Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia | Zendy

Raúl D. Santos | Zendy; Andrea Ruzza | Zendy; G. Kees Hovingh | Zendy; Albert Wiegman | Zendy; François Mach | Zendy; Christopher E. Kurtz | Zendy; Andrew Hamer | Zendy; Ian Bridges | Zendy; Andrea Bartuli | Zendy; Jean Bergeron | Zendy; T Szamosi | Zendy; Saikat Santra | Zendy; Claudia Stefanutti | Zendy; Olivier Descamps | Zendy; Susanne GreberPlatzer | Zendy; Ilse K. Luirink | Zendy; John J.P. Kastelein | Zendy; Daniel Gaudet | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia

Author(s) -

Raúl D. Santos,

Andrea Ruzza,

G. Kees Hovingh,

Albert Wiegman,

François Mach,

Christopher E. Kurtz,

Andrew Hamer,

Ian Bridges,

Andrea Bartuli,

Jean Bergeron,

T Szamosi,

Saikat Santra,

Claudia Stefanutti,

Olivier Descamps,

Susanne GreberPlatzer,

Ilse K. Luirink,

John J.P. Kastelein,

Daniel Gaudet

Publication year - 2020

Publication title -

new england journal of medicine

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2019910

Subject(s) - evolocumab , familial hypercholesterolemia , pcsk9 , kexin , proprotein convertase , medicine , alirocumab , monoclonal antibody , monoclonal , heterozygote advantage , endocrinology , cholesterol , lipoprotein , ldl receptor , antibody , genetics , biology , immunology , allele , gene , apolipoprotein a1

Evolocumab, a fully human monoclonal antibody directed against proprotein convertase subtilisin-kexin type 9, is widely used in adult patients to lower low-density lipoprotein (LDL) cholesterol levels. Its effects in pediatric patients with heterozygous familial hypercholesterolemia are not known.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research